Loading…

Target-specific mononuclear and binuclear rhenium() tricarbonyl complexes as upcoming anticancer drugs

Metal complexes have gradually been attracting interest from researchers worldwide as potential cancer therapeutics. Driven by the many side effects of the popular platinum-based anticancer drug cisplatin, the tireless endeavours of researchers have afforded strategies for the design of appropriate...

Full description

Saved in:
Bibliographic Details
Published in:RSC advances 2022-07, Vol.12 (31), p.2264-2295
Main Authors: Sharma, Ajay, Kar, Binoy, Das, Utpal, Paira, Priyankar
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Metal complexes have gradually been attracting interest from researchers worldwide as potential cancer therapeutics. Driven by the many side effects of the popular platinum-based anticancer drug cisplatin, the tireless endeavours of researchers have afforded strategies for the design of appropriate metal complexes with minimal side effects compared to cisplatin and its congeners to limit the unrestricted propagation of cancer. In this regard, transition metal complexes, especially rhenium-based complexes are being identified and highlighted as promising cancer theranostics, which are endowed with the ability to detect and annihilate cancer cells in the body. This is attributed the amazing photophysical properties of rhenium complexes together with their ability to selectively attack different organelles in cancer cells. Therefore, this review presents the properties of different rhenium-based complexes to highlight their recent advances as anticancer agents based on their cytotoxicity results. In this review, rhenium-based complexes are highlighted as promising cancer theranostics, which are endowed with the ability to detect and annihilate cancer cells in the body.
ISSN:2046-2069
2046-2069
DOI:10.1039/d2ra03434d